Other Intangible Assets, Net

3 Months Ended

Mar. 31, 2013

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Other Intangible Assets Disclosure

8.       Other intangible assets, net

		March 31,	December 31,
		2013	2012
		$’M	$’M
		________________	________________
Amortized intangible assets
	Intellectual property rights acquired for currently marketed products	2,446.7	2,462.0
	Acquired product technology	710.0	710.0
	Other intangible assets	44.4	44.5
		________________	________________
		3,201.1	3,216.5
Unamortized intangible assets
	Intellectual property rights acquired for IPR&D	557.0	231.0
		________________	________________
		3,758.1	3,447.5
Less: Accumulated amortization		(1,100.9)	(1,059.4)
		________________	________________
		2,657.2	2,388.1
		________________	________________

As at March 31, 2013the net book value of intangible assets allocated to the SP segment was $ 1,209.5 million (December 31, 2012: $1,238.0 million),to the HGT segment was $782.4 million (December 31, 2012: $474.6 million) and to the RM segment was $665.3 million (December 31, 2012: $675.5 million).

The change in the net book value of other intangible assets for the three monthsto March 31, 2013and 2012is shown in the table below:

	Other intangible assets
	2013	2012
	$’M	$’M
	________________	________________
As at January 1,	2,388.1	2,493.0
Acquisitions	328.5	22.0
Amortization charged	(45.9)	(45.8)
Foreign currency translation	(13.5)	19.8
	________________	________________
As at March 31,	2,657.2	2,489.0
	________________	________________

In the three months to March 31, 2013 the Company acquired intangible assets totaling $328.5 million, relating to intangible assets acquired with Premacure and Lotus (see Note 2 for further details).

Management estimates that the annual amortization charge in respect of intangible assets held at March 31, 2013will be approximately $198million for each of the five years to March 31, 2018.Estimated amortization expense can be affected by various factors including future acquisitions, disposals of product rights, regulatory approval and subsequent amortization of acquired IPR&D projects, foreign exchange movements and the technological advancement and regulatory approval of competitor products.